Plain-English translation of NCT05563766 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an FDA-approved antifungal medication, can help improve treatment results for people with esophageal cancer. Researchers believe this medication may work by blocking certain pathways in cancer cells that help tumors grow, especially when used alongside standard chemotherapy and radiation. The goal is to see if adding this medication increases the chances that the cancer is completely eliminated before surgery.
Esophageal cancer is serious and hard to treat, and doctors are looking for better ways to fight it. This medication may work against specific pathways that cancer cells use to survive and grow, so researchers want to test whether adding it to standard treatment could give patients better outcomes.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice a day for two weeks before your standard chemotherapy and radiation begin. After you finish chemotherapy and radiation, you would continue taking the medication for another 6–8 weeks. During this time, you'll have regular clinic visits where doctors will check for side effects, monitor your blood levels, and perform heart rhythm tests (EKGs). Once chemotherapy and radiation are complete, you'll have imaging scans to make sure the cancer hasn't spread, and if all looks good, you'll proceed to surgery to remove the affected part of your esophagus. Your surgical tissue will be examined to see if the cancer was completely eliminated.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States